38256-94-9

Basic information

• Product Name: (2-ethoxyethyl)methylamine(SALTDATA: HCl)
• Synonyms: (2-ethoxyethyl)methylamine(SALTDATA: HCl);N-(2-Ethoxyethyl)-N-MethylaMine;(2-ethoxyethyl)methylamine hydrochloride;2-ethoxy-N-methylEthanamine;(2-ethoxyethyl)(methyl)amine
• CAS NO: 38256-94-9
• Molecular Formula: C₅H₁₃NO
• Molecular Weight: 103.16282
• Product Categories: Aliphatics, Miscellaneous Reagents
• Mol File: 38256-94-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 193.43°C (rough estimate)
• Appearance: /
• Density: 0.8363
• Refractive Index: 1.4147 (estimate)
• CAS DataBase Reference: (2-ethoxyethyl)methylamine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: (2-ethoxyethyl)methylamine(SALTDATA: HCl)(38256-94-9)
• EPA Substance Registry System: (2-ethoxyethyl)methylamine(SALTDATA: HCl)(38256-94-9)

Safety Data

• Hazardous Substances Data: 38256-94-9(Hazardous Substances Data)

Usage

Uses

N-(2-Ethoxyethyl)-N-methylamine, can be used for the preparation of various pharmaceutical compounds. It can be used for the synthesis of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors. It can also be utilized for the preparation of Benzomorphan-related compounds.

Upstream product

• 67-56-1 methanol 
• 110-76-9 2-ethoxy-1-ethanamine 
• 98139-68-5 2-Ethoxyethyl methanesulphonate 
• 74-89-5 methylamine 

Relevant articles and documents

PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.